REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019.CA Cancer J Clin. Jan 2019;69(1):7-34.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA,
Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer
J Clin. Nov-Dec 2018;68(6):394-424.
3. Sheikh MA, Althouse AD, Freese KE, et al. USA Endometrial
Cancer Projections to 2030: should we be concerned? Future Oncol.2014;10(16):2561-2568.
4. Chen W, Zheng R, Baade PD, et al. Cancer statistics in
China, 2015. CA: a cancer journal for clinicians.2016;66(2):115-132.
5. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of
the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in
Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl
1:S105-S143.
6. Kumar S, Podratz KC, Bakkum-Gamez JN, et al. Prospective
assessment of the prevalence of pelvic, paraaortic and high paraaortic
lymph node metastasis in endometrial cancer. Gynecol Oncol.2014;132(1):38-43.
7. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment
of lymphatic dissemination in endometrial cancer: a paradigm shift in
surgical staging. Gynecol Oncol. 2008;109(1):11-18.
8. Panici PB, Basile S, Maneschi F, et al. Systematic Pelvic
Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial
Carcinoma: Randomized Clinical Trial. J Natl Cancer I. Dec 3
2008;100(23):1707-1716.
9. Kitchener H, Swart AMC, Qian W, Amos C, Parmer MKB. Efficacy
of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC
trial): a randomised study. (vol 373, pg 125, 2009). Lancet. May
23 2009;373(9677):1764-1764.
10. Bogani G, Ditto A, Chiappa V, Raspagliesi F. Sentinel node
mapping in endometrial cancer. Transl Cancer Res. Oct
2019;8(6):2218-2219.
11. Schiavone MB, Scelzo C, Straight C, et al. Survival of
Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node
Mapping. Ann Surg Oncol. Jul 2017;24(7):1965-1971.
12. Baiocchi G, Faloppa CC, Mantoan H, et al. Para-aortic
lymphadenectomy can be omitted in most endometrial cancer patients at
risk of lymph node metastasis. J Surg Oncol. Aug 1
2017;116(2):220-226.
13. Cusano E, Myers V, Samant R, et al. Prognostic Significance
of Lymphovascular Space Invasion in the Absence of Lymph Node Metastases
in Early-Stage Endometrial Cancer. Int J Gynecol Cancer. Jun
2018;28(5):890-894.
14. Bosse T, Peters EEM, Creutzberg CL, et al. Substantial
lymph-vascular space invasion (LVSI) is a significant risk factor for
recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2
trials. Eur J Cancer. Sep 2015;51(13):1742-1750.
15. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant
chemoradiotherapy versus radiotherapy alone for women with high-risk
endometrial cancer (PORTEC-3): final results of an international,
open-label, multicentre, randomised, phase 3 trial. Lancet Oncol.Mar 2018;19(3):295-309.
16. McMillia N, Motter A. NCCN Clinical Practice Guidelines in
Oncology of Uterine Neoplasms 2020 v1. 2020;www.nccn.org. Accessed May 1, 2020.
17. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO
Consensus Conference on Endometrial Cancer Diagnosis, Treatment and
Follow-up. Int J Gynecol Cancer. Jan 2016;26(1):2-30.
18. Takeuchi M, Matsuzaki K, Harada M. Evaluating Myometrial
Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view
Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging.Magn Reson Med Sci. 2018;17(1):28-34.
19. Peters EEM, Bartosch C, McCluggage WG, et al.
Reproducibility of lymphovascular space invasion (LVSI) assessment in
endometrial cancer. Histopathology. 2019;75(1):128-136.
20. Stålberg K, Bjurberg M, Borgfeldt C, et al. Lymphovascular
space invasion as a predictive factor for lymph node metastases and
survival in endometrioid endometrial cancer - a Swedish Gynecologic
Cancer Group (SweGCG) study. Acta oncologica (Stockholm, Sweden).2019;58(11):1628-1633.
21. Boothe D, Wolfson A, Christensen M, Francis S, Werner TL,
Gaffney DK. Lymphovascular Invasion in Endometrial Cancer: Prognostic
Value and Implications on Adjuvant Radiation Therapy Use. Am J
Clin Oncol. 2019;42(7):549-554.